Satake, Tomoyuki http://orcid.org/0000-0001-9445-7738
Morizane, Chigusa
Maruki, Yuta
Ohba, Akihiro
Nagashio, Yoshikuni
Kondo, Shunsuke
Hijioka, Susumu
Ueno, Hideki
Okusaka, Takuji
Article History
Received: 16 November 2021
Accepted: 5 May 2022
First Online: 30 May 2022
Declarations
:
: Takuji Okusaka reports a consulting/advisory relationship with Taiho Pharmaceutical, Daiichi Sankyo, Sumitomo Dainippon Pharma, Bristol Myers Squibb, AstraZeneca, Eisai, and Nihon Servier; research funding from Eli Lilly Japan, MSD, AstraZeneca, Eisai, Chugai Pharmaceutical, Novartis Pharma, Sumitomo Dainippon Pharma, Bristol Myers Squibb, Taiho Pharmaceutical, and Baxter; honoraria from Meiji Seika Pharma, Teijin Pharma, Eli Lilly Japan, MSD, AstraZeneca, AbbVie, Eisai, Ono Pharmaceutical, Yakult Honsha, Daiichi Sankyo, Chugai Pharmaceutical, Nihon Servier, and Novartis Pharma; and scientific advisory board fees from AstraZeneca, Nippon Shinyaku, Nihon Servier, Novartis Pharma, Pfizer, and Mundipharma. Chigusa Morizane has received a speaker honorarium from Nihon Servier and Yakult Honsha. Akihiro Ohba has received a speaker honorarium from Ono Pharmaceutical, Taiho Pharmaceutical, and Yakult Honsha, and research funding from Ono Pharmaceutical, and Chugai Pharmaceutical. The other authors declare that they have no conflict of interest.
: This study was conducted in accordance with the principles laid down in the 1964 Declaration of Helsinki and its later amendments, and the protocol was approved by the Ethics Committee of the National Cancer Center (Approval No. 2018-149) and all the institutions participating in this study. Approval for review of the hospital records was obtained from the Institutional Review Board of the National Cancer Center and the need for informed consent from the patients was waived in view of the retrospective nature of the study.